At a glance
ClinicalIndex Comparison Record- ✓Advanced, surgically unresectable colorectal cancer
- ✓Measurable disease by imaging (at least one lesion accurately measurable in one dimension)
- ✓Histologically confirmed adenocarcinoma of colon or rectum
- ✓ECOG performance status 0, 1, or 2
- ✕Any systemic therapy for metastatic or locally recurrent disease
- ✕Candidate for surgical resection of metastatic/locally advanced disease
- ✕Non-adenocarcinoma histology of colon or rectum
- ✕Pregnancy or lactation; women of childbearing potential without pregnancy test
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated Advanced Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Capecitabine, and 1 other intervention for Cancer. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This is a Phase II study of the drug combination of Oxaliplatin, Avastin and capecitabine. This is an open-label study.
Study Details
Timeline
Interventions
Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine